Department of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, FL 33431, United States.
Department of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, FL 33431, United States.
Biochem Pharmacol. 2022 Apr;198:114979. doi: 10.1016/j.bcp.2022.114979. Epub 2022 Feb 24.
Tauopathies are neurodegenerative diseases characterized by the deposition of abnormal tau in the brain. To date, there are no disease-modifying therapies approved by the U.S. Food and Drug Administration (US FDA) for the treatment of tauopathies. In the past decades, extensive efforts have been provided to develop disease-modifying therapies to treat tauopathies. Specifically, exploring existing drugs with the intent of repurposing for the treatment of tauopathies affords a reasonable alternative to discover potent drugs for treating these formidable diseases. Drug repurposing will not only reduce formulation and development stage effort and cost but will also take a key advantage of the established toxicological studies, which is one of the main causes of clinical trial failure of new molecules. In this review, we provide an overview of the current treatment strategies for tauopathies and the recent progress in drug repurposing as an alternative approach to treat tauopathies.
tau 病是一种神经退行性疾病，其特征是大脑中异常 tau 的沉积。迄今为止，还没有获得美国食品和药物管理局（US FDA）批准的用于治疗 tau 病的疾病修饰疗法。在过去的几十年中，人们为开发疾病修饰疗法以治疗 tau 病做出了广泛的努力。具体来说，探索现有药物的重新定位意图，以用于治疗 tau 病，为发现治疗这些棘手疾病的有效药物提供了合理的选择。药物再利用不仅可以减少制剂和开发阶段的努力和成本，而且还可以利用已建立的毒理学研究的主要优势，这是新分子临床试验失败的主要原因之一。在这篇综述中，我们概述了 tau 病的当前治疗策略以及药物再利用作为治疗 tau 病的替代方法的最新进展。
